RNA vs TER · rev $22.6M vs P/E 76, rev $2.61B
Atrium Therapeutics, Inc. Common Stock (RNA) versus Teradyne Inc (TER) — a side-by-side from cached financials, not a winner call.
Atrium Therapeutics, Inc. Common Stock (RNA) is a biotechnology company listed on NASDAQ.
Teradyne Inc (TER) is a semiconductor equipment & materials company listed on NASDAQ.
Latest reported RNA revenue for 2026-06-30 was $22.6M. Net income was -$36.8M. Revenue was up 15.3% from 2026-03-31 to 2026-06-30. RNA currently screens at market cap $217.5M.
Latest reported TER revenue for 2026-06-28 was $2.61B. Net income was $773.4M. TER currently screens at market cap $63.96B and trailing P/E 75.7.
RNA currently screens at market cap $217.5M. TER currently screens at market cap $63.96B and trailing P/E 75.7.
Not investment advice. Open the RNA and TER stock pages for the full models.
Not investment advice.